129 related articles for article (PubMed ID: 32718298)
1. Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis.
Ashraf MAB; Zahid A; Ashraf S; Waquar S; Iqbal S; Malik A
Anticancer Agents Med Chem; 2020; 20(17):2106-2113. PubMed ID: 32718298
[TBL] [Abstract][Full Text] [Related]
2. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
3. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
4. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
5. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
[TBL] [Abstract][Full Text] [Related]
6. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.
Reinholz MM; Iturria SJ; Ingle JN; Roche PC
Breast Cancer Res Treat; 2002 Jun; 74(3):255-69. PubMed ID: 12206515
[TBL] [Abstract][Full Text] [Related]
9. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.
Zhang J; Lu Y; Dai J; Yao Z; Kitazawa R; Kitazawa S; Zhao X; Hall DE; Pienta KJ; Keller ET
Prostate; 2004 Jun; 59(4):360-9. PubMed ID: 15065084
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
Todenhöfer T; Hennenlotter J; Schmiedel BJ; Hohneder A; Grimm S; Kühs U; Salih HR; Bühring HJ; Fehm T; Gakis G; Blumenstock G; Aufderklamm S; Schilling D; Stenzl A; Schwentner C
Prostate; 2013 Jan; 73(2):162-8. PubMed ID: 22715006
[TBL] [Abstract][Full Text] [Related]
12. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
[TBL] [Abstract][Full Text] [Related]
13. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
Thoms JW; Dal Pra A; Anborgh PH; Christensen E; Fleshner N; Menard C; Chadwick K; Milosevic M; Catton C; Pintilie M; Chambers AF; Bristow RG
Br J Cancer; 2012 Aug; 107(5):840-6. PubMed ID: 22871886
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy.
Puzone R; Paleari L; Montefiore F; Ruggiero L; Puntoni M; Maffezzini M; Bobbio B; Marroni P; Libener R; Betta PG
Int J Biol Markers; 2010; 25(4):200-6. PubMed ID: 21161941
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
18. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.
Leto G; Incorvaia L; Badalamenti G; Tumminello FM; Gebbia N; Flandina C; Crescimanno M; Rini G
Clin Exp Metastasis; 2006; 23(2):117-22. PubMed ID: 16841234
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.
Carlinfante G; Vassiliou D; Svensson O; Wendel M; Heinegård D; Andersson G
Clin Exp Metastasis; 2003; 20(5):437-44. PubMed ID: 14524533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
